Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK plus advanced tumors-论文-万方医学网

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK plus advanced tumors

导出原文传递

翻译打印收藏纠错

作者： Hurtado, Felipe K. ^[1] ; de Braud, Filippo ^[2] ; De Castro Carpeno, Javier ^[3] ; de Miguel Luken, Maria Jose ^[4] ; Wang, Ding ^[5] ; Scott, Jeffrey ^[6] ; Lau, Yvonne Y. ; McCulloch, Tracey ; Mau-Sorensen, Morten

作者单位： Novartis Pharmaceut, E Hanover, NJ 07936 USA ^[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy ^[2] Hosp Univ La Paz, Med Oncol Dept, IdiPAZ, Madrid, Spain ^[3] CIOCC Grp Hosp Madrid, Hosp Sanchinarro, Madrid, Spain ^[4] Henry Ford Canc Inst, Detroit, MI USA ^[5] Rigshosp, Dept Oncol, Copenhagen, Denmark ^[6]

关键词 ALK inhibitor Ceritinib Drug&8211 drug interaction Pharmacokinetics CYP3A Midazolam Warfarin

发布时间 2022-09-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除